Max J. Hyman, BA

Center for Health and the Social Sciences, Department of Medicine, University of Chicago, Chicago, Illinois

JCP
HIV Diagnosis and PrEP Prescription in Commercially Insured Persons with Bipolar Disorder
Original Research

December 8, 2025

PrEP use among commercially insured people with bipolar disorder was critically low, with fewer than 1% prescribed PrEP.
, ,

Consensus Report on XT Use in Practice

Figure: Graphic promoting Consensus Report on Xanomeline-Trospium; colorful net design shown with JCP logo in lower left.

Subscribe to read
more articles

Subscribe